In this randomized Phase @ trial , patients with NSCLC who had previously failed EGFR-TKI therapy were randomized to receive intravenous pemetrexed ( @mg/m ( @ ) for @ days -LSB- one cycle -RSB- ) or docetaxel ( @mg/m ( @ ) for @ days -LSB- one cycle -RSB- ) .